Dose Finding and Food Effect Studies of a Novel Abiraterone Acetate Formulation for Oral Suspension in Comparison to a Reference Formulation in Healthy Male Subjects

Currently approved formulations of the androgen synthesis inhibitor abiraterone acetate (AA) consist of multiple tablets administered daily in a fasted state. Removing the food effect and switching to a suspension formulation is expected to improve the pharmacokinetic profile and facilitate drug adm...

Full description

Saved in:

Bibliographic Details
Published in:	Pharmaceutics Vol. 13; no. 12; p. 2171
Main Authors:	Jordán, Tamás, Basa-Dénes, Orsolya, Angi, Réka, Orosz, János, Ötvös, Zsolt, Ujhelyi, Andrea, Filipcsei, Genovéva, Molnár, László, Solymosi, Tamás, Glavinas, Hristos, Capone, Dominic, Whitfield, Nicola, McDermott, John, McKenzie, Litza, Shurety, Lauren, Duus, Elizabeth Manning
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 16-12-2021 MDPI
Subjects:	abiraterone acetate Androgens Bioavailability Bioequivalence Cellulose dose reduction Drug dosages Dysphagia FDA approval Food Lactose Metastasis minimizing food effect Pharmacokinetics Prostate cancer New Zealand United Kingdom > UK United States > US China Germany dose reduction abiraterone acetate minimizing food effect
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Currently approved formulations of the androgen synthesis inhibitor abiraterone acetate (AA) consist of multiple tablets administered daily in a fasted state. Removing the food effect and switching to a suspension formulation is expected to improve the pharmacokinetic profile and facilitate drug administration for patients with late-stage prostate cancer. Two four-sequence, four-period randomized crossover investigations were undertaken to establish the pharmacokinetic profiles of single doses of commercially available Zytiga , as the reference AA (R-AA), and a novel tablet for oral suspension (TOS). Four single doses of TOS (from 62.5 to 250 mg) were compared in study C01, and two single doses each of TOS (250 mg) and R-AA (1000 mg) were compared under fasted and fed (modified fasted for R-AA) conditions in C02. Plasma concentrations of abiraterone over time were measured, and pharmacokinetic parameters were calculated. Each doubling of the dose of TOS was associated with a greater than 3-fold increase in exposure. A single dose of TOS (250 mg) exhibited similar exposure over 24 h, whether given fasted (625 ng × h/mL) or fed (485 ng × h/mL). A single dose of TOS (250 mg) was associated with higher (fasted, = 0.028) or equivalent exposure (fed) compared to 1000 mg R-AA fasted (532 ng × h/mL). Substantially higher exposures were seen with 1000 mg R-AA under modified fasted conditions compared to TOS, irrespective of prandial status ( < 0.001). TOS was generally safe and well tolerated in the study. A 250 mg dose of a novel AA formulation for oral suspension demonstrated bioequivalence to 1000 mg R-AA under fasted conditions. This novel TOS formulation also addresses some of the limitations of current AA treatment, including low bioavailability, high variability in systemic exposure and a large food effect. It may offer an alternative for patients with dysphagia or discomfort with swallowing large pills.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1999-4923 1999-4923
DOI:	10.3390/pharmaceutics13122171